Opioids
AHA today launched an updated Opioid Stewardship Hub, featuring the latest tools and resources to help hospitals and health systems address the opioid epidemic.
AHA developed a suite of opioid stewardship strategies, guides and other resources to help hospitals and health systems address the growing epidemic.
For people struggling with opioid use disorder, the COVID-19 pandemic has become a crisis on top of a crisis. These tools and resources were developed to help your hospital or health system build or advance opioid stewardship during this critical time and beyond.
Mobilize community partnerships to develop and implement prevention, intervention, and treatment activities for opioid use and misuse. These resources can help.
You can develop a successful opioid stewardship practice. Use these resources to help recognize, prevent and treat opioid misuse and save lives.
This toolkit, released by the AHA, provides guidance and information to hospitals and health systems on how they can partner with patients, clinicians and communities to address the opioid epidemic. Developed with input from a multidisciplinary team of front-line clinicians and subject matter…
Remove Stigma: Talk with Your Patients About Substance Use Disorder. CDC guide on addressing stigma and promoting open conversations. CDC 07/2022.
The Food and Drug Administration last week required certain labeling updates for opioid pain medicines in an effort to reduce unnecessary prescribing and prevent complications such as opioid-induced hyperalgesia, when an opioid causes an increase in pain or increased sensitivity to pain.
The Food and Drug Administration April 3 announced that it will require manufacturers of opioid analgesics used in outpatient settings to modify their Risk Evaluation and Mitigation Strategy within 180 days to make prepaid mail-back envelopes and educational materials on safe opioid disposal…
In response to Drug Enforcement Administration proposals to limit telehealth prescriptions for buprenorphine and other controlled substances after the COVID-19 public health emergency to a 30-day supply unless the prescriber or referring clinician have evaluated the patient in person, AHA today…